A Trial of a Group A Plus Group C Meningococcal Polysaccharide-protein Conjugate Vaccine in African Infants

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 1995 Mar 1

PMID 7876610

Citations 36

Authors

P A Twumasi Jr

S Kumah

A Leach

T J ODempsey

S J Ceesay

J Todd

C V Broome

G M Carlone

L B Pais

P K Holder

Affiliations

Soon will be listed here.

Abstract

The safety and immunogenicity of a group A plus group C meningococcal polysaccharide-CRM197 conjugate vaccine was evaluated in 304 8- to 10-week-old Gambian infants. Infants were immunized with one, two, or three doses of conjugate vaccine or with two doses of a meningococcal A plus C polysaccharide vaccine. The conjugate vaccine produced few systemic side effects, and local reactions were similar to those produced by the polysaccharide vaccine. Postvaccination group A meningococcal polysaccharide antibody levels, measured by ELISA, increased progressively after one, two, or three doses of conjugate vaccine. However, one dose of conjugate vaccine given at the age of 6 months induced a higher group C meningococcal antibody response than did two doses of conjugate vaccine given at 2 and 6 months. Two doses of conjugate vaccine induced higher levels of antibody than did two doses of polysaccharide vaccine. Thus, this new meningococcal conjugate vaccine proved to be safe and immunogenic.

Citing Articles

Efficacy and Effectiveness of the Meningococcal Conjugate Group A Vaccine MenAfriVac in Preventing Recurrent Meningitis Epidemics in Sub-Saharan Africa.

Viviani S Vaccines (Basel). 2022; 10(4).

PMID: 35455366 PMC: 9027557. DOI: 10.3390/vaccines10040617.

[From a pathogen's genome to an effective vaccine: the four-component meningococcal serogroup B vaccine].

Abad R, Martinon-Torres F, Santolaya M, Banzhoff A, Gonzalez-Inchausti C, Grana M Rev Esp Quimioter. 2019; 32(3):208-216.

PMID: 31148440 PMC: 6609940.

Factors contributing to the immunogenicity of meningococcal conjugate vaccines.

Broker M, Berti F, Costantino P Hum Vaccin Immunother. 2016; 12(7):1808-24.

PMID: 26934310 PMC: 4964817. DOI: 10.1080/21645515.2016.1153206.

Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal Vaccination.

Holme D, Findlow H, Sow S, Idoko O, Preziosi M, Carlone G Clin Infect Dis. 2015; 61 Suppl 5:S563-9.

PMID: 26553689 PMC: 4639486. DOI: 10.1093/cid/civ505.

From Epidemic Meningitis Vaccines for Africa to the Meningitis Vaccine Project.

Aguado M, Jodar L, Granoff D, Rabinovich R, Ceccarini C, Perkin G Clin Infect Dis. 2015; 61 Suppl 5:S391-5.

PMID: 26553665 PMC: 4639495. DOI: 10.1093/cid/civ593.